Targeted Therapies for Hodgkin Lymphoma

Chapter 3

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss current research focused on the treatment of Hodgkin lymphoma with targeted therapies.

Chapter 1

Hodgkin Lymphoma Overview

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss characteristics of Hodgkin lymphoma, standard treatment options for patients, and educating patients about side effects and other factors as they enter into treatment.

Chapter 2

Autologous Stem Cell Transplant for Patients with Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the approximate 20% of patients with relapsed/refractory Hodgkin lymphoma and factors and risks related to autologous stem cell transplant, including psychosocial factors.

Chapter 4

Treating Patients With Hodgkin Lymphoma with Targeted Therapies

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss issues that affect patients who are treated with targeted therapies.

Chapter 5

Efficacy and Safety of Targeted Therapies for Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the efficacy and safety of targeted therapies for the treatment of Hodgkin lymphoma, specifically the results from the AETHERA study.

Chapter 6

Managing Adverse Events in Patients Being Treated with Brentuximab Vedotin

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss strategies to manage various adverse events that occur in patients with Hodgkin lymphoma being treated with brentuximab vedotin.

Chapter 7

Research in New Agents for Relapsed/Refractory Hodgkin Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss current research related to the use of nivolumab and pembrolizumab for patients with relapsed/refractory Hodgkin lymphoma.

Chapter 8

Overview of Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the first-line treatment approach and prognostic factors used in anaplastic large cell lymphoma.

Chapter 9

Treatment Options in Relapsed/Refractory Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the options in terms of treatment for patients with relapsed/refractory anaplastic large cell lymphoma and novel agents in this patient population.

Chapter 10

Managing Adverse Events in Relapsed/Refractory Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the most common adverse events in patients being treated with novel agents for relapsed/refractory anaplastic large cell lymphoma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs